Compare TNXP & RBKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TNXP | RBKB |
|---|---|---|
| Founded | 2007 | 1860 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 192.9M | 185.5M |
| IPO Year | 2008 | 2018 |
| Metric | TNXP | RBKB |
|---|---|---|
| Price | $12.79 | $17.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 525.4K | 35.1K |
| Earning Date | 05-11-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 91.75 | ★ 215.00 |
| EPS | N/A | ★ 0.20 |
| Revenue | ★ $13,107,000.00 | $2,984,000.00 |
| Revenue This Year | $558.11 | N/A |
| Revenue Next Year | $38.29 | N/A |
| P/E Ratio | ★ N/A | $86.15 |
| Revenue Growth | ★ 29.85 | N/A |
| 52 Week Low | $10.03 | $9.41 |
| 52 Week High | $69.65 | $17.99 |
| Indicator | TNXP | RBKB |
|---|---|---|
| Relative Strength Index (RSI) | 57.23 | 65.65 |
| Support Level | $12.43 | $15.18 |
| Resistance Level | $15.19 | $17.92 |
| Average True Range (ATR) | 1.01 | 0.42 |
| MACD | 0.20 | 0.05 |
| Stochastic Oscillator | 87.20 | 70.97 |
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Rhinebeck Bancorp Inc is the holding company for Rhinebeck Bank, which is a New York-chartered stock savings bank. It provides a full range of banking and financial services to consumer and commercial customers. Financial services, including investment advisory and financial product sales, are offered through a division of the Bank doing business as Rhinebeck Asset Management. The Bank's primary business activity is accepting deposits from the general public and using those funds together with borrowings, to originate commercial real estate loans (which include multi-family real estate loans and commercial construction loans), commercial business loans and indirect automobile loans, and to purchase one- to four-family residential real estate loans and investment securities.